<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on November 21, 2026 at 7:35 am by All in One SEO v5.0.5.1 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://helixgatebiotechreview.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Helixgate</title>
		<link><![CDATA[https://helixgatebiotechreview.com]]></link>
		<description><![CDATA[Helixgate]]></description>
		<lastBuildDate><![CDATA[Sat, 21 Nov 2026 07:08:11 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://helixgatebiotechreview.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://www.biocentury.com/article/661619/marrow-delivering-sirna-to-bone-marrow?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661619/marrow-delivering-sirna-to-bone-marrow?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Marrow: Delivering siRNA to bone marrow</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 07:08:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661677/innovation-radar-where-to-intervene-in-neutrophil-extracellular-traps?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661677/innovation-radar-where-to-intervene-in-neutrophil-extracellular-traps?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Innovation Radar:  Where to intervene in neutrophil extracellular traps</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 07:08:08 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661548/private-european-biopharmas-make-bigger-acquisitions-in-2026?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661548/private-european-biopharmas-make-bigger-acquisitions-in-2026?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Private European biopharmas make bigger acquisitions in 2026</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 07:08:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661702/flagship-pours-100m-into-new-u-k-company-creation-lab?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661702/flagship-pours-100m-into-new-u-k-company-creation-lab?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Flagship pours £100M into new U.K. company creation lab</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 07:07:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661706/aribio-s-split-phase-iii-result-reflects-a-mixed-ctad?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661706/aribio-s-split-phase-iii-result-reflects-a-mixed-ctad?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>AriBio’s split Phase III result reflects a mixed CTAD</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 07:07:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661670/biotech-will-find-a-way-the-coins-act-won-t-stop-china-biotech-innovation?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661670/biotech-will-find-a-way-the-coins-act-won-t-stop-china-biotech-innovation?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Biotech will find a way: The COINS Act won’t stop China biotech innovation</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 07:07:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/biotech-china-deals-venture-returns-summit-stock/874912/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/biotech-china-deals-venture-returns-summit-stock/874912/]]></link>
			<title>This week in charts: Biotech investors’ China bets are already paying off</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 02:29:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/celldex-eczema-nchroma-layoffs-isomorphic-merck-teva-vitrivax/875241/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/celldex-eczema-nchroma-layoffs-isomorphic-merck-teva-vitrivax/875241/]]></link>
			<title>Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 02:29:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/erasca-kras-pancreatic-cancer-drug-results-revolution-rasonque/875314/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/erasca-kras-pancreatic-cancer-drug-results-revolution-rasonque/875314/]]></link>
			<title>Erasca data add to pressure facing Revolution’s breakthrough cancer drug</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 02:29:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/race-first-psilocybin-blockbuster-compass-usona/875369/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/race-first-psilocybin-blockbuster-compass-usona/875369/]]></link>
			<title>Will the first approved psychedelic become a blockbuster?</title>
			<pubDate><![CDATA[Sat, 21 Nov 2026 02:29:47 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://phys.org/news/2026-11-optical-dna-yeast-genomes-chromosome.html]]></guid>
			<link><![CDATA[https://phys.org/news/2026-11-optical-dna-yeast-genomes-chromosome.html]]></link>
			<title>Optical DNA mapping assembles yeast genomes at chromosome scale</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 22:01:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.pharmavoice.com/news/race-first-psilocybin-blockbuster-compass-usona/875270/]]></guid>
			<link><![CDATA[https://www.pharmavoice.com/news/race-first-psilocybin-blockbuster-compass-usona/875270/]]></link>
			<title>Will the first approved psychedelic become a blockbuster?</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 20:59:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.labiotech.eu/partner/ai-antibody-design-validation/]]></guid>
			<link><![CDATA[https://www.labiotech.eu/partner/ai-antibody-design-validation/]]></link>
			<title>Two days in cell-free, three days in CHO: antibody sequence to data with Biointron’s RushDATA&#x2122;</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 17:43:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program]]></link>
			<title>Accelerated Approval Program</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 14:50:54 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/accelerated-approval-program/ongoing-non-malignant-hematological-neurological-and-other-disorder-indications-accelerated]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/accelerated-approval-program/ongoing-non-malignant-hematological-neurological-and-other-disorder-indications-accelerated]]></link>
			<title>Ongoing | Non-malignant Hematological, Neurological, and Other Disorder Indications Accelerated Approvals</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 14:50:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/drug-alerts-and-statements/fda-publishes-new-batch-product-specific-guidances-facilitate-generic-drug-development]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/drug-alerts-and-statements/fda-publishes-new-batch-product-specific-guidances-facilitate-generic-drug-development]]></link>
			<title>FDA Publishes New Batch of Product-Specific Guidances to Facilitate Generic Drug Development</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 14:50:32 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/guidances-drugs/upcoming-product-specific-guidances-generic-drug-product-development]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/guidances-drugs/upcoming-product-specific-guidances-generic-drug-product-development]]></link>
			<title>Upcoming Product-Specific Guidances for Generic Drug Product Development</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 14:50:29 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/accelerated-approval-program/verified-clinical-benefit-non-malignant-hematological-neurological-and-other-disorder-indications]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/accelerated-approval-program/verified-clinical-benefit-non-malignant-hematological-neurological-and-other-disorder-indications]]></link>
			<title>Verified Clinical Benefit | Non-malignant Hematological, Neurological, and Other Disorder Indications Accelerated Approvals</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 14:49:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/development-resources/written-requests-issued-pediatric-studies]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/development-resources/written-requests-issued-pediatric-studies]]></link>
			<title>Written Requests Issued for Pediatric Studies</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 14:49:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/development-resources/pediatric-exclusivity-granted]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/development-resources/pediatric-exclusivity-granted]]></link>
			<title>Pediatric Exclusivity Granted</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 14:49:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files]]></link>
			<title>Drugs@FDA Data Files</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 14:46:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/pharmalot/2026/11/19/merck-isomorphic-ai-deal-china-pharmaceutical-supply-chain/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/pharmalot/2026/11/19/merck-isomorphic-ai-deal-china-pharmaceutical-supply-chain/?utm_campaign=rss]]></link>
			<title>STAT+: Pharmalittle: We’re reading about a Merck AI deal, China and the pharma supply chain, and more</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 14:39:30 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/pharmalot/2026/11/19/china-pharma-biotech-clinical-trials-security-risk-patents-drug-development/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/pharmalot/2026/11/19/china-pharma-biotech-clinical-trials-security-risk-patents-drug-development/?utm_campaign=rss]]></link>
			<title>STAT+: Big drugmakers tell House committee they will halt clinical trials at some hospitals in China</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 14:39:29 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/19/maha-pac-midterm-election-spending-fda-questions-after-heidi-overton/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/19/maha-pac-midterm-election-spending-fda-questions-after-heidi-overton/?utm_campaign=rss]]></link>
			<title>STAT+: MAHA PAC’s steakhouse spend</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 14:39:29 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/20/biotech-news-early-results-for-alterome-kras-drug-arrive/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/20/biotech-news-early-results-for-alterome-kras-drug-arrive/?utm_campaign=rss]]></link>
			<title>STAT+: Early results for Alterome’s KRAS drug for pancreas, lung and colon cancer arrive</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 14:39:28 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/pharmalot/2026/11/20/sanofi-eyeing-insmed-ai-speeding-drug-development/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/pharmalot/2026/11/20/sanofi-eyeing-insmed-ai-speeding-drug-development/?utm_campaign=rss]]></link>
			<title>STAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and more</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 14:39:27 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/about-fda/office-health-advancement/office-health-advancement-oha-guidance-documents]]></guid>
			<link><![CDATA[http://www.fda.gov/about-fda/office-health-advancement/office-health-advancement-oha-guidance-documents]]></link>
			<title>Office of Health Advancement (OHA) Guidance Documents</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 13:09:38 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/medical-device-correction-update-lunar-g3-bpap-system-model-lg3800-30vt]]></guid>
			<link><![CDATA[http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/medical-device-correction-update-lunar-g3-bpap-system-model-lg3800-30vt]]></link>
			<title>Medical Device Correction Update  Luna® G3 BPAP System (Model LG3800-30VT)</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 11:24:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/CTAD-2026-bms-cobenfy-eases-alzheimer&apos;s-psychosis-as-expected-but-safety-events-raise-questions]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/CTAD-2026-bms-cobenfy-eases-alzheimer&apos;s-psychosis-as-expected-but-safety-events-raise-questions]]></link>
			<title>CTAD 2026: BMS’ Cobenfy eases Alzheimer’s psychosis as expected but safety events raise questions</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 06:39:16 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/routine-psa-machine-learning-model-improves-prostate-cancer-triage-in-multicenter-study/]]></guid>
			<link><![CDATA[https://bioengineer.org/routine-psa-machine-learning-model-improves-prostate-cancer-triage-in-multicenter-study/]]></link>
			<title>Routine PSA Machine Learning Model Improves Prostate Cancer Triage in Multicenter Study</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 06:00:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/genotype-d1-hepatitis-b-virus-protein-mutations-follow-phase-dependent-structural-shifts/]]></guid>
			<link><![CDATA[https://bioengineer.org/genotype-d1-hepatitis-b-virus-protein-mutations-follow-phase-dependent-structural-shifts/]]></link>
			<title>Genotype D1 Hepatitis B Virus Protein Mutations Follow Phase-Dependent Structural Shifts</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 06:00:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/case-study-analyzes-recurrent-obstructing-nipple-duct-stones-in-two-lactating-patients/]]></guid>
			<link><![CDATA[https://bioengineer.org/case-study-analyzes-recurrent-obstructing-nipple-duct-stones-in-two-lactating-patients/]]></link>
			<title>Case Study Analyzes Recurrent Obstructing Nipple Duct Stones in Two Lactating Patients</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 05:59:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/staged-bone-grafts-enable-stock-joint-implants-in-hemifacial-microsomia/]]></guid>
			<link><![CDATA[https://bioengineer.org/staged-bone-grafts-enable-stock-joint-implants-in-hemifacial-microsomia/]]></link>
			<title>Staged Bone Grafts Enable Stock Joint Implants in Hemifacial Microsomia</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 05:59:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.sciencedaily.com/releases/2026/11/261118065512.htm]]></guid>
			<link><![CDATA[https://www.sciencedaily.com/releases/2026/11/261118065512.htm]]></link>
			<title>Something strange is living beneath the skin of deep-sea pigs</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 05:38:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/fda-clears-sanofis-type-3-gaucher-therapy-infilbray]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/fda-clears-sanofis-type-3-gaucher-therapy-infilbray]]></link>
			<title>FDA clears Sanofi&#8217;s Type 3 Gaucher therapy Infilbray</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 05:08:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/uk-modernises-gene-therapy-definition-regulatory-revamp]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/uk-modernises-gene-therapy-definition-regulatory-revamp]]></link>
			<title>UK modernises gene therapy definition in regulatory revamp</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 05:08:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/novartis-raises-forecasts-three-key-growth-products]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/novartis-raises-forecasts-three-key-growth-products]]></link>
			<title>Novartis raises forecasts for three key growth products</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 05:08:31 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/isomorphic-adds-msd-partner-roster-and-other-deals]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/isomorphic-adds-msd-partner-roster-and-other-deals]]></link>
			<title>Isomorphic adds MSD to partner roster, and other deals</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 05:08:30 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661491/ai3bio-resetting-the-immune-system-with-in-vivo-t-cell-depletion?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661491/ai3bio-resetting-the-immune-system-with-in-vivo-t-cell-depletion?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>ai3Bio: Resetting the immune system with in vivo T cell depletion</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 01:46:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661666/overton-wasn-t-anyone-s-first-choice-but-the-alternative-is-likely-to-be-much-worse?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661666/overton-wasn-t-anyone-s-first-choice-but-the-alternative-is-likely-to-be-much-worse?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Overton wasn’t anyone’s first choice, but the alternative is likely to be much worse</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 01:46:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661663/with-lembaz-approved-beren-turns-to-diagnosis-and-patient-access?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661663/with-lembaz-approved-beren-turns-to-diagnosis-and-patient-access?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>With Lembaz approved, Beren turns to diagnosis and patient access</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 01:46:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661617/seawolf-making-dna-durable-redosable-and-able-to-enter-the-nucleus?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661617/seawolf-making-dna-durable-redosable-and-able-to-enter-the-nucleus?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Seawolf: Making DNA durable, redosable, and able to enter the nucleus</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 01:45:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bio.news/latest-news/amr-awareness-week-c-diff-patient-finds-her-voice-in-advocacy/]]></guid>
			<link><![CDATA[https://bio.news/latest-news/amr-awareness-week-c-diff-patient-finds-her-voice-in-advocacy/]]></link>
			<title>AMR Awareness Week: C. diff patient finds her voice in advocacy</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 01:35:54 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.pharmaceutical-business-review.com/news/fda-rejects-summits-ivonescimab-application/]]></guid>
			<link><![CDATA[https://www.pharmaceutical-business-review.com/news/fda-rejects-summits-ivonescimab-application/]]></link>
			<title>FDA rejects Summit’s ivonescimab application for lung cancer</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 00:24:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.pharmaceutical-business-review.com/news/astrazeneca-fda-approval-imfinzi-combo-mibc/]]></guid>
			<link><![CDATA[https://www.pharmaceutical-business-review.com/news/astrazeneca-fda-approval-imfinzi-combo-mibc/]]></link>
			<title>AstraZeneca secures FDA approval for Imfinzi combo in MIBC</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 00:24:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.pharmaceutical-business-review.com/news/astrazeneca-fda-approval-imfinzi-combo-mibc/]]></guid>
			<link><![CDATA[https://www.pharmaceutical-business-review.com/news/astrazeneca-fda-approval-imfinzi-combo-mibc/]]></link>
			<title>AstraZeneca secures FDA approval for Imfinzi combo in MIBC</title>
			<pubDate><![CDATA[Fri, 20 Nov 2026 00:24:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/about-fda/accelerating-rare-disease-cures-arc-program/rare-disease-drug-approvals]]></guid>
			<link><![CDATA[http://www.fda.gov/about-fda/accelerating-rare-disease-cures-arc-program/rare-disease-drug-approvals]]></link>
			<title>Rare Disease Drug Approvals</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 22:22:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/19/hims-noom-enter-peptide-market-mainstream-products-health-risks/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/19/hims-noom-enter-peptide-market-mainstream-products-health-risks/?utm_campaign=rss]]></link>
			<title>STAT+: Peptide market poised to explode with new Hims and Noom launches</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 20:03:22 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/19/erasca-kras-targeted-treatment-new-data-pancreatic-cancer/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/19/erasca-kras-targeted-treatment-new-data-pancreatic-cancer/?utm_campaign=rss]]></link>
			<title>STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 19:45:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://helixgatebiotechreview.com/]]></guid>
			<link><![CDATA[https://helixgatebiotechreview.com/]]></link>
			<title>Home</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 03:39:54 +0000]]></pubDate>
		</item>
				</channel>
</rss>
